Eminence Capital, LP Catalent, Inc. Transaction History

Eminence Capital, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$41.39 - $81.0 $63.5 Million - $124 Million	1,533,669 Added 151.3%	2,547,332 $115 Million
Q3 2022 Nov 14, 2022	SELL	$72.36 - $113.1 $2.44 Million - $3.81 Million	-33,666 Reduced 3.21%	1,013,663 $73.3 Million
Q2 2022 Aug 15, 2022	BUY	$87.2 - $114.05 $29.9 Million - $39.1 Million	342,616 Added 48.62%	1,047,329 $112 Million
Q1 2022 May 16, 2022	BUY	$94.19 - $124.49 $44.2 Million - $58.4 Million	469,124 Added 199.13%	704,713 $78.2 Million
Q4 2021 Feb 14, 2022	BUY	$119.57 - $139.07 $28.2 Million - $32.8 Million	235,589 New	235,589 $30.2 Million

513

149M

575K

2.03M

Ticker CTLT
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 179,896,000
Market Cap $11B
Description
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...

Get notified when there are updates to the investment portfolio of Eminence Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Eminence Capital, LP with notifications on news.